Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $184.08 and last traded at $184.08, with a volume of 11 shares. The stock had previously closed at $191.13.
Genmab A/S Trading Down 3.7 %
The company has a 50 day moving average of $206.99 and a 200-day moving average of $216.46. The firm has a market capitalization of $12.16 billion, a P/E ratio of 10.51 and a beta of 1.08.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a net margin of 36.30% and a return on equity of 19.75%.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
- Five stocks we like better than Genmab A/S
- How to Buy Gold Stock and Invest in Gold
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- The Role Economic Reports Play in a Successful Investment Strategy
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to Find Undervalued Stocks
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
